Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Biomarkers for cystic fibrosis drug development.

Muhlebach MS, Clancy JP, Heltshe SL, Ziady A, Kelley T, Accurso F, Pilewski J, Mayer-Hamblett N, Joseloff E, Sagel SD.

J Cyst Fibros. 2016 Nov;15(6):714-723. doi: 10.1016/j.jcf.2016.10.009. Epub 2016 Oct 27. Review.

PMID:
28215711
2.

Control of lung defence by mucins and macrophages: ancient defence mechanisms with modern functions.

Janssen WJ, Stefanski AL, Bochner BS, Evans CM.

Eur Respir J. 2016 Oct;48(4):1201-1214. doi: 10.1183/13993003.00120-2015. Epub 2016 Sep 1.

3.

The proteomics of lung injury in childhood: challenges and opportunities.

Pereira-Fantini PM, Tingay DG.

Clin Proteomics. 2016 Feb 29;13:5. doi: 10.1186/s12014-016-9106-0. eCollection 2016. Review.

4.

Proteomic analysis of nasal epithelial cells from cystic fibrosis patients.

Jeanson L, Guerrera IC, Papon JF, Chhuon C, Zadigue P, Prulière-Escabasse V, Amselem S, Escudier E, Coste A, Edelman A.

PLoS One. 2014 Sep 30;9(9):e108671. doi: 10.1371/journal.pone.0108671. eCollection 2014.

5.

Redox balance in cystic fibrosis.

Ziady AG, Hansen J.

Int J Biochem Cell Biol. 2014 Jul;52:113-23. doi: 10.1016/j.biocel.2014.03.006. Epub 2014 Mar 20. Review.

6.

Expression of calgranulin A/B heterodimer after acute inhalation of endotoxin: proteomic approach and validation.

Michel O, Doyen V, Leroy B, Bopp B, Dinh DH, Corazza F, Wattiez R.

BMC Pulm Med. 2013 Nov 15;13:65. doi: 10.1186/1471-2466-13-65.

7.

Directional secretomes reflect polarity-specific functions in an in vitro model of human bronchial epithelium.

Pillai DK, Sankoorikal BJ, Johnson E, Seneviratne AN, Zurko J, Brown KJ, Hathout Y, Rose MC.

Am J Respir Cell Mol Biol. 2014 Feb;50(2):292-300. doi: 10.1165/rcmb.2013-0188OC.

8.

Altered microRNA signatures in sputum of patients with active pulmonary tuberculosis.

Yi Z, Fu Y, Ji R, Li R, Guan Z.

PLoS One. 2012;7(8):e43184. doi: 10.1371/journal.pone.0043184. Epub 2012 Aug 10.

9.

Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.

Yang J, Eiserich JP, Cross CE, Morrissey BM, Hammock BD.

Free Radic Biol Med. 2012 Jul 1;53(1):160-71. doi: 10.1016/j.freeradbiomed.2012.05.001. Epub 2012 May 8.

10.

Down-regulation of cytokine-induced interleukin-8 requires inhibition of p38 mitogen-activated protein kinase (MAPK) via MAPK phosphatase 1-dependent and -independent mechanisms.

Dauletbaev N, Eklove D, Mawji N, Iskandar M, Di Marco S, Gallouzi IE, Lands LC.

J Biol Chem. 2011 May 6;286(18):15998-6007. doi: 10.1074/jbc.M110.205724. Epub 2011 Mar 15.

11.

Using bacterial biomarkers to identify early indicators of cystic fibrosis pulmonary exacerbation onset.

Rogers GB, Hoffman LR, Johnson MW, Mayer-Hamblett N, Schwarze J, Carroll MP, Bruce KD.

Expert Rev Mol Diagn. 2011 Mar;11(2):197-206. doi: 10.1586/erm.10.117. Review.

12.

Plasma lipidomics reveals potential prognostic signatures within a cohort of cystic fibrosis patients.

Ollero M, Astarita G, Guerrera IC, Sermet-Gaudelus I, Trudel S, Piomelli D, Edelman A.

J Lipid Res. 2011 May;52(5):1011-22. doi: 10.1194/jlr.P013722. Epub 2011 Feb 18.

13.

Protein biomarkers in cystic fibrosis research: where next?

Pattison SH, Elborn JS.

Genome Med. 2010 Dec 16;2(12):88. doi: 10.1186/gm209.

14.

Applications of proteomic technologies for understanding the premature proteolysis of CFTR.

Henderson MJ, Singh OV, Zeitlin PL.

Expert Rev Proteomics. 2010 Aug;7(4):473-86. doi: 10.1586/epr.10.42. Review.

15.

Airways disease: phenotyping heterogeneity using measures of airway inflammation.

Siddiqui S, Brightling CE.

Allergy Asthma Clin Immunol. 2007 Jun 15;3(2):60-9. doi: 10.1186/1710-1492-3-2-60. Epub 2007 Jun 15.

16.

A novel lipidomic strategy reveals plasma phospholipid signatures associated with respiratory disease severity in cystic fibrosis patients.

Guerrera IC, Astarita G, Jais JP, Sands D, Nowakowska A, Colas J, Sermet-Gaudelus I, Schuerenberg M, Piomelli D, Edelman A, Ollero M.

PLoS One. 2009 Nov 6;4(11):e7735. doi: 10.1371/journal.pone.0007735.

17.

Sputum proteomics in inflammatory and suppurative respiratory diseases.

Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, Innes JA, Porteous DJ, Greening AP.

Am J Respir Crit Care Med. 2008 Sep 1;178(5):444-52. doi: 10.1164/rccm.200703-409OC. Epub 2008 Jun 19.

18.

A novel proteolytic cascade generates an extracellular matrix-derived chemoattractant in chronic neutrophilic inflammation.

Gaggar A, Jackson PL, Noerager BD, O'Reilly PJ, McQuaid DB, Rowe SM, Clancy JP, Blalock JE.

J Immunol. 2008 Apr 15;180(8):5662-9.

19.

Inflammatory markers of lung disease in adult patients with cystic fibrosis.

Levy H, Kalish LA, Huntington I, Weller N, Gerard C, Silverman EK, Celedón JC, Pier GB, Weiss ST.

Pediatr Pulmonol. 2007 Mar;42(3):256-62.

20.

Clinical proteomics: present and future prospects.

Verrills NM.

Clin Biochem Rev. 2006 May;27(2):99-116.

Supplemental Content

Support Center